Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
2.2
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Third quarter1 September 2025 to 31 May 2026ConsolidatedJapanese GAAPNet Sales25,279¥ millionYear on year +2.2%Progress 74.1%
Operating profit1,800¥ millionYear on year -2.9%Progress 70.7%
Ordinary income1,745¥ millionYear on year -6.6%Progress 71.4%
Net income attributable to owners of the parent1,166¥ millionYear on year -17.4%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥80.82
Financial position at period-end
Total assets49,948¥ million
of which net assets 16,427 ¥ millionEquity ratio 32.3%vs. prior year-end +1.4pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenueHealthcare Business ¥14,798,512 thousand (YoY +3.0%), Pharmaceuticals Business ¥1,887,097 thousand (YoY +2.8%), Department Store Business ¥3,504,893 thousand (YoY 0.0%), Food-Service Business ¥1,913,392 thousand (YoY +7.5%), Real Estate and Construction Contracting Business ¥1,607,650 thousand (YoY -13.6%), Other Businesses ¥1,567,535 thousand
Segment profitHealthcare Business ¥1,699,599 thousand (YoY -13.6%), Pharmaceuticals Business ¥230,722 thousand (YoY +54.5%), Department Store Business ¥46,606 thousand (YoY -14.5%), Food-Service Business ¥12,412 thousand, Real Estate and Construction Contracting Business ¥-29,166 thousand, Other Businesses ¥-131,116 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥34,137 million (YoY +4.5%)
Operating profit¥2,545 million (YoY +5.6%)
Ordinary income¥2,445 million (YoY +0.1%)
Profit attributable to owners of the parent¥1,545 million (YoY +6.7%)
Revision to Earnings ForecastNo revision
Annual Dividend Forecast¥34 → ¥36
Factors Behind Changes in Business Performance
Revenue increased due to higher revenue and income from the Pharmaceuticals Business, which maintained strong performance, as well as higher revenue from the Healthcare Business and other factors. In Pharmaceuticals, the company cited increased orders for over-the-counter pharmaceutical OEM products and sales driven by medical generic pharmaceuticals. In Healthcare, it cited strong orders and growth in the number of recurring mail-order purchases.
Disclosure regarding the going concern assumption
No applicable matters.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationAdditions: None; exclusions: None
Impairment lossNone (impairment loss on fixed assets)
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of non-current assets ¥5,368 thousand, Insurance proceeds received ¥23,623 thousand / Extraordinary loss Loss on sale of fixed assets ¥1,367 thousand, Loss on Disposal of Fixed Assets ¥4,151 thousand
Depreciation and amortization¥875,009 thousand
Availability of Supplementary Financial Results MaterialsNo
Availability of Financial Results BriefingNone; attendees: Not disclosed
Issued Shares at Period-End14,559,699 Shares
Treasury Shares at Period-End94 Shares
| Item | Details |
|---|---|
| Fiscal Period Classification | Third quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 September 2025 to 31 May 2026 |
| Net Sales | ¥25,279 million (YoY +2.2%) |
| Operating profit | ¥1,800 million (YoY -2.9%) |
| Ordinary income | ¥1,745 million (YoY -6.6%) |
| Profit attributable to owners of the parent | ¥1,166 million (YoY -17.4%) |
| Net income per share | ¥80.82 |
| Equity ratio | End of the current fiscal period 32.3 / End of previous period 30.9 |
| Total assets | ¥49,948 million |
| Net assets | ¥16,427 million |
| Full-year earnings forecast | Net Sales ¥34,137 million (YoY +4.5%) / Operating profit ¥2,545 million (YoY +5.6%) / Ordinary income ¥2,445 million (YoY +0.1%) / Profit attributable to owners of the parent ¥1,545 million (YoY +6.7%) |
| Revision to Earnings Forecast | No revision |
| Annual Dividend Forecast | ¥34 → ¥36 |
| Segment revenue | Healthcare Business ¥14,798,512 thousand (YoY +3.0%), Pharmaceuticals Business ¥1,887,097 thousand (YoY +2.8%), Department Store Business ¥3,504,893 thousand (YoY 0.0%), Food-Service Business ¥1,913,392 thousand (YoY +7.5%), Real Estate and Construction Contracting Business ¥1,607,650 thousand (YoY -13.6%), Other Businesses ¥1,567,535 thousand |
| Segment profit | Healthcare Business ¥1,699,599 thousand (YoY -13.6%), Pharmaceuticals Business ¥230,722 thousand (YoY +54.5%), Department Store Business ¥46,606 thousand (YoY -14.5%), Food-Service Business ¥12,412 thousand, Real Estate and Construction Contracting Business ¥-29,166 thousand, Other Businesses ¥-131,116 thousand |
| Depreciation and amortization | ¥875,009 thousand |
| Impairment loss | None (impairment loss on fixed assets) |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of non-current assets ¥5,368 thousand, Insurance proceeds received ¥23,623 thousand / Extraordinary loss Loss on sale of fixed assets ¥1,367 thousand, Loss on Disposal of Fixed Assets ¥4,151 thousand |
| Disclosure regarding the going concern assumption | No applicable matters. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | Additions: None; exclusions: None |
| Availability of Supplementary Financial Results Materials | No |
| Availability of Financial Results Briefing | None; attendees: Not disclosed |
| Issued Shares at Period-End | 14,559,699 Shares |
| Treasury Shares at Period-End | 94 Shares |
| Factors Behind Changes in Business Performance | Revenue increased due to higher revenue and income from the Pharmaceuticals Business, which maintained strong performance, as well as higher revenue from the Healthcare Business and other factors. In Pharmaceuticals, the company cited increased orders for over-the-counter pharmaceutical OEM products and sales driven by medical generic pharmaceuticals. In Healthcare, it cited strong orders and growth in the number of recurring mail-order purchases. |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company attributed the increase in revenue to higher revenue and income from the Pharmaceuticals Business, which maintained strong performance, as well as higher revenue from the Healthcare Business. It also cited strong orders for over-the-counter pharmaceutical OEM products, sales of in-house products, and orders and subscription purchases in the Healthcare Business. The company did not specify why consolidated profit fell below the year-earlier level.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.